PD-1/PD-L1 interaction up-regulates MDR1/P-gp expression in breast cancer cells via PI3K/AKT and MAPK/ERK pathways.

PD-1/PD-L1 interaction up-regulates MDR1/P-gp expression in breast cancer cells via PI3K/AKT and MAPK/ERK pathways.
复制标题

DOI:
10.18632/oncotarget.21914
复制
发表时间:
2017-11-21
期刊:
影响因子:
--
通讯作者:
Li D
Li D
中科院分区:
其他
文献类型:
--
作者:
Liu S;Chen S;Yuan W;Wang H;Chen K;Li D;Li D

文献摘要

参考文献

被引文献

相似文献

程序性细胞死亡配体1(PD-L1)是一种在肿瘤细胞上表达的免疫抑制分子。通过与T细胞上的程序性细胞死亡-1(PD-1)相互作用,它抑制免疫反应。由于PD-L1在癌细胞上的表达增加了其化疗耐药性,我们研究了PD-L1与乳腺癌细胞中多药耐药1/P-gp(MDR 1/P-gp)表达之间的相关性。使用组织微阵列对乳腺癌组织进行分析,发现PD-L1和MDR 1/P-gp蛋白水平之间存在显著相关性。PD-L1表达的增加与淋巴结转移和肿瘤组织学分级相关。此外,PD-L1与PD-1的相互作用诱导AKT和ERK的磷酸化,导致PI 3 K/AKT和MAPK/ERK通路的激活以及乳腺癌细胞中MDR 1/P-gp表达的增加。PD-1/PD-L1相互作用也增加了与阿霉素孵育的乳腺癌细胞的存活率。这些结果表明,PD-1/PD-L1抑制可能通过抑制乳腺癌细胞中的MDR 1/P-gp表达来增加化疗疗效。
Programmed cell death ligand 1 (PD-L1) is an immunosuppressive molecule expressed on tumor cells. By interacting with programmed cell death-1 (PD-1) on T cells, it inhibits immune responses. Because PD-L1 expression on cancer cells increases their chemoresistance, we investigated the correlation between PD-L1 and multidrug resistance 1/ P-glycoprotein (MDR1/P-gp) expression in breast cancer cells. Analysis of breast cancer tissues using tissue microarrays revealed a significant correlation between PD-L1 and MDR1/P-gp protein levels. Increased expression of PD-L1 was associated with lymph node metastasis and histological tumor grade. In addition, interaction of PD-L1 with PD-1 induced phosphorylation of AKT and ERK, resulting in the activation of PI3K/AKT and MAPK/ERK pathways and increased MDR1/P-gp expression in breast cancer cells. The PD-1/PD-L1 interaction also increased survival of breast cancer cells incubated with doxorubicin. These findings suggest that the PD-1/PD-L1 inhibition may increase chemotherapy efficacy by inhibiting the MDR1/P-gp expression in breast cancer cells.
DOI: 10.1111/cas.12560
发表时间: 2015-01
期刊: Cancer science
影响因子: 5.7
作者:
Kim HJ;Im SA;Keam B;Ham HS;Lee KH;Kim TY;Kim YJ;Oh DY;Kim JH;Han W;Jang IJ;Kim TY;Park IA;Noh DY
通讯作者: Noh DY
DOI: 10.18632/oncotarget.5583
发表时间: 2015-10-20
期刊: Oncotarget
影响因子: --
作者:
Qin T;Zeng YD;Qin G;Xu F;Lu JB;Fang WF;Xue C;Zhan JH;Zhang XK;Zheng QF;Peng RJ;Yuan ZY;Zhang L;Wang SS
通讯作者: Wang SS
DOI: 10.1073/pnas.1003345107
发表时间: 2010-04-27
影响因子: 11.1
作者:
Matsuzaki, Junko;Gnjatic, Sacha;Odunsi, Kunle
通讯作者: Odunsi, Kunle
DOI: 10.1016/j.cellimm.2005.07.007
发表时间: 2005-06-01
影响因子: 4.3
作者:
Nielsen, C;Ohm-Laursen, L;Lillevang, ST
通讯作者: Lillevang, ST
DOI: 10.1002/cncr.22588
发表时间: 2007-04-15
期刊: CANCER
影响因子: 6.2
作者:
Inman, Brant A.;Sebo, Thomas J.;Kwon, Eugene D.
通讯作者: Kwon, Eugene D.